Delivery Order SPE2DE21D7020-SPE2D625F1KLU
- Not listed
- Boston Scientific Corp, a leading global medical technology company headquartered in Marlborough, Massachusetts, was awarded a delivery order valued at $7,593.10 for EnRoute TCAR stents on August 14, 2025. This fixed-price contract with economic price adjustment is scheduled for ultimate completion by August 21, 2025, and will be performed at Boston Scientific's Marlborough facility. The award is being funded through the Defense Health Agency's Medical Supply Chain, a defense-focused federal...
- Boston Scientific Corp was awarded a delivery order valued at $3,326.30 by the Defense Health Agency's Medical Supply Chain for enroute TCAR stents, with performance in Marlborough, MA. The contract was awarded on August 12, 2025, with an ultimate completion date of August 19, 2025, and utilizes fixed-price pricing with economic price adjustment. This is an open competition award with no set-aside designation, allowing Boston Scientific to compete directly against other qualified vendors in...
- Boston Scientific Corp has been awarded a delivery order valued at $11,389.65 for enroute TCAR stents under a Defense Health Agency Medical Supply Chain contract. The award, issued on September 2, 2025, with an ultimate completion date of September 9, 2025, represents a fixed-price contract with economic price adjustment provisions. The work will be performed at Boston Scientific's facility in Marlborough, Massachusetts. No set-aside designation was applied to this award, indicating open...
- The Defense Health Agency's Medical Supply Chain awarded a delivery order valued at $3,326.30 to Boston Scientific Corp for EnRoute TCAR stents on July 25, 2025, with an ultimate completion date of August 1, 2025. This fixed-price contract with economic price adjustment carries no set-aside designation, allowing Boston Scientific to compete openly in the federal marketplace. The work will be performed at Boston Scientific's facility in Marlborough, Massachusetts, where the company manufactures...
- This federal contract award was issued by the Defense Health Agency (DHA) to Boston Scientific Corp, a global medical technology company headquartered in Marlborough, Massachusetts. The $3,796.55 fixed-price with economic price adjustment delivery order contract is for the provision of ENROUTE TCAR STENTS, which are specialized medical devices used in cardiovascular procedures. The contract has an ultimate completion date of July 16, 2025 and was awarded on July 9, 2025. It is not designated...
- This is a federal contract award to Boston Scientific Corp, a global medical technology company, by the Defense Health Agency (DHA) for the delivery of ENROUTE TCAR stents. The contract is a Delivery Order with a Fixed Price with Economic Price Adjustment pricing type, and a ceiling value of $3,796.55. The contract does not have a set-aside designation. The performance period extends to June 10, 2025. Boston Scientific is also the holder of two federal Indefinite Delivery Vehicles (IDVs) with...
- Boston Scientific Corp, a leading global medical technology company headquartered in Marlborough, Massachusetts, has been awarded a delivery order valued at $1,303.44 by the Defense Health Agency's Medical Supply Chain program. This fixed-price contract with economic price adjustment, issued on July 28, 2025, is scheduled for completion by August 4, 2025. The award represents a non-set-aside competitive procurement, with performance occurring at Boston Scientific's Marlborough facility. As a...
- Boston Scientific Corp, a global medical technology company headquartered in Marlborough, Massachusetts, has been awarded a delivery order valued at $3,010.72 for wallstents under the Defense Health Agency's Medical Supply Chain program. The contract, awarded on August 11, 2025, with an ultimate completion date of August 18, 2025, utilizes fixed-price pricing with economic price adjustment. This delivery order represents part of Boston Scientific's broader federal portfolio, which encompasses...
- Boston Scientific Corp, a global medical technology company headquartered in Marlborough, Massachusetts, was awarded a delivery order valued at $13,027.08 by the Defense Health Agency's Medical Supply Chain on August 4, 2025. The contract, which utilizes fixed-price pricing with economic price adjustment, is scheduled for completion by August 11, 2025. The award represents a non-set-aside competitive procurement, and the place of performance is Boston Scientific's facility in Marlborough, MA. As...
- Boston Scientific Corp, a Marlborough, Massachusetts-based global medical technology company, was awarded a delivery order by the Defense Health Agency's Medical Supply Chain on July 22, 2025, with an ultimate completion date of July 29, 2025. The contract, valued at $1,727.26, is structured as a fixed price agreement with economic price adjustment provisions and carries no set-aside designation, indicating open competition in the federal marketplace. The award description references medical...
- SPE2DE21D7020Indefinite Delivery Contract
- SPE2DE21D7020-SPE2D625F1KLUDelivery Order
Boston Scientific Corp, headquartered in Marlborough, Massachusetts, was awarded a fixed-price delivery order valued at $7,593.10 by the Defense Health Agency's Medical Supply Chain on August 20, 2025, with an ultimate completion date of August 27, 2025. The contract involves the supply of enroute TCAR (transcarotid artery revascularization) stents, specialized cardiovascular intervention devices used in minimally invasive procedures. This delivery order was competitively awarded with no set-aside designation, reflecting Boston Scientific's established capability as a prime contractor providing critical medical technologies to federal healthcare agencies. The fixed-price structure includes economic price adjustment provisions to accommodate potential cost variations during the brief contract performance period. This award represents a continuation of Boston Scientific's substantial presence within the federal medical supply chain, particularly through the Defense Health Agency's procurement vehicle. The company maintains an extensive portfolio of cardiovascular and interventional medical devices supplied to federal agencies including the Department of Veterans Affairs and Defense Logistics Agency. The enroute TCAR stent delivery fulfills specialized requirements for advanced vascular intervention capabilities within the Defense Health Agency's healthcare system, supporting the agency's ability to provide state-of-the-art cardiovascular treatment options to military beneficiaries and federal healthcare recipients.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.6k | 8/20/25 |